Cargando…

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports

BACKGROUND: Advanced-stage hepatocellular carcinoma (HCC), especially huge HCC or portal vein tumour thrombus (PVTT), is difficult to treat, and the prognosis is poor. The advantages of hepatic artery infusion chemotherapy (HAIC) combined with targeted therapy and immunotherapy for this complex dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Yuan, Jin, Wenbiao, Sun, Honghua, Jin, Dehao, Kang, Dongxu, Li, Zhiyu, Piao, Longzhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542216/ https://www.ncbi.nlm.nih.gov/pubmed/37791067 http://dx.doi.org/10.2147/JHC.S426174

Ejemplares similares

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
por: Xiao, Yongqiang, et al.
Publicado: (2023)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy
por: Wu, Zhiqiang, et al.
Publicado: (2020)

Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
por: Wang, Yajing, et al.
Publicado: (2023)

Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment
por: Wu, De-Di, et al.
Publicado: (2022)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma
por: Liu, Yulong, et al.
Publicado: (2022)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
por: Liu, Juanfang, et al.
Publicado: (2021)

Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma
por: Wei, Zhanqi, et al.
Publicado: (2023)

Case Report: Hepatic Artery Infusion Chemotherapy After Stage I ALPPS in a Patient With Huge HCC
por: Zhuo, Wenfeng, et al.
Publicado: (2021)

DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC
por: Kondo, Yasuteru, et al.
Publicado: (2022)

Case report and literature review: PET/CT in the evaluation of response to treatment of liver metastasis from colorectal cancer with DEBIRI-TACE
por: Jin, Lan, et al.
Publicado: (2023)

Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
por: Lee, Jaejun, et al.
Publicado: (2021)

Hepatic Artery Infusion Chemotherapy
por: Tuchmann, A., et al.
Publicado: (1990)

Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report
por: Chen, Zhihong, et al.
Publicado: (2023)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study
por: Wei, Fuqun, et al.
Publicado: (2021)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma
por: Xu, Yongkang, et al.
Publicado: (2022)

Enucleated eyes after failed intra-arterial infusion of chemotherapy for unilateral retinoblastoma: histopathologic evaluation of vitreous seeding
por: Kim, Jonathan, et al.
Publicado: (2011)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy
por: Liu, Baojiang, et al.
Publicado: (2023)

Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
por: Sun, Bo, et al.
Publicado: (2022)

Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC
por: Li, Ting, et al.
Publicado: (2023)

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
por: Hou, Wei, et al.
Publicado: (2022)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
por: Li, Xiaomi, et al.
Publicado: (2023)

Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
por: Wu, Juan, et al.
Publicado: (2023)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
por: Lam, Clarissa, et al.
Publicado: (2023)

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study
por: Zhang, Tian-Qi, et al.
Publicado: (2023)

Hepatic Arterial Infusion Chemotherapy for Patients with Huge Unresectable Hepatocellular Carcinoma
por: Tsai, Wei-Lun, et al.
Publicado: (2014)

Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study
por: Chang, Xu, et al.
Publicado: (2023)

Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan
por: Nishikawa, Hiroki, et al.
Publicado: (2012)

Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study
por: Chen, Song, et al.
Publicado: (2023)

The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review
por: Yuanren, Gao, et al.
Publicado: (2023)

Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
por: Yu, Yi, et al.
Publicado: (2021)

Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy
por: Oh, Myung Jin, et al.
Publicado: (2013)

Hepatic Arterial Infusion Chemotherapy for Liver Metastases Following Standard Chemotherapy for Pancreatic Cancer
por: Endo, Shinya, et al.
Publicado: (2020)

Modern Prospection for Hepatic Arterial Infusion Chemotherapy in Malignancies with Liver Metastases
por: Liang, Yi-Hsin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8j91523gl8ntcm479dc70a2m37